C
COMPANY PROFILE
CUREator
Valuation
$100–250M
Last recorded · 2021
Total funding
$10–50M
Disclosed equity funding
At a glance
- Status
- Operational
- Headquarters
- Australia
- Open positions
- None listed
- Dealroom signal
- 16.8/100
- Investment activity
- 11 companies, latest Sep 2025
- Capital deployed
- $13M
- Preferred round
- GRANT
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| EARLY VC✓Equity / VC | Nov 2021 | $40M | $160M | Undisclosed | ↗ |
Showing the latest 1 of 1 recorded eventsBook a demo for the full funding history →
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
CeretasBrisbane, AustraliaTherapeutic ultrasound technology for neurological disease treatment
$12Mvaluation
SynaptraBIOSydney, AustraliaAI-powered drug discovery for neurodegenerative diseases
→
xCystence BioDistrict of Tuggeranong, AustraliaTherapeutics for Polycystic Kidney Disease treatment
→
Skin2NeuronSydney, AustraliaRegenerative medicine transforming hair follicles into millions of pure neurons, gene modification free
→
Sydney Neuroimaging Analysis CentreSydney, AustraliaAI-powered neuroimaging analysis for clinical trials and research
→
RedenlabMelbourne, AustraliaRedenlab’s digital speech platform supports the delivery of meaningful outcomes through the objective measurement of communication
→
DentericMelbourne, AustraliaDeveloping vaccines for treating and preventing severe periodontal disease, with the ultimate goal of improving the health of people with this disease
$36Mvaluation
Perx HealthSydney, AustraliaDisease management that is simple, exciting and rewarding Perx runs programs on behalf of hospitals, pharmaceutical companies and insurers
$7.8Mvaluation
CytophenixPerth, AustraliaRapid antimicrobial susceptibility tests delivering swift, accurate results to combat infections and antimicrobial resistance
$5.2Mvaluation
GILZRxAustraliaGILZRx is developing an anti-inflammatory therapeutic small molecule for the treatment of inflammatory and autoimmune diseases, including lupus.
$2.6Mvaluation
OccuRxMelbourne, AustraliaPrimary focus is on the development of innovative therapeutic strategies for the treatment of ophthalmic disorders associated with retinal fibrosis
$38Mvaluation
11 profiles shownExplore the complete relationship graph →
Founders
Hidden — book a demo/100
quality score
Key operators
Hidden — book a demo
quality score
Potential founders
Hidden — book a demo
likely future founders
Startup mafia
Hidden — book a demo
alumni-founded startups
Talent movements
Hidden — book a demo in · Hidden — book a demo out
past 12 months
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about CUREator on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See CUREator’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.